Cancer Drug Tanstrive Launched: A promising news for cancer patients in India has come to light. The well-known American pharma company Eli Lilly and Company (Eli Lilly) has launched its new anti-cancer drug ‘Tanstrive’ (Tanstrive) in the Indian market. This drug is specially designed for patients who have a specific genetic condition called ‘RET’ gene mutation.
What is the specialty of this medicine?
Traditionally, cancer treatment involves chemotherapy that affects both cancer and healthy cells throughout the body. But TanStrive is a ‘targeted therapy’. It only targets cancer-promoting gene changes, thereby slowing tumor growth.
Price and dosage
According to the company, the drug is available in dosages of 40 mg to 160 mg. A box is priced at around Rs 2.15 lakh, which is enough for 14 days of treatment. This drug, taken twice a day, is being considered as a new revolution in the world of cancer treatment.
Importance of gene based treatment
Experts say that now medicines are being ‘personalised’ rather than ‘general’. Doctors first check the genes of the patient and only then prescribe such drugs, which makes the treatment more accurate.
(Note: This information is for educational purposes. Always consult your family doctor or oncologist for your treatment.)
